Get the Stockscreener App
1.125
0.54%
-0.005
Brainstorm Cell Therapeutics Inc stock is traded at $1.125, with a volume of 1.16M.
It is down -0.54% in the last 24 hours and down -14.31% over the past month.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
See More
Previous Close:
$1.12
Open:
$1.13
24h Volume:
1.16M
Relative Volume:
1.00
Market Cap:
$8.89M
Revenue:
-
Net Income/Loss:
$-16.63M
P/E Ratio:
-2.6163
EPS:
-0.43
Net Cash Flow:
$-21.84M
1W Performance:
+3.14%
1M Performance:
-14.31%
6M Performance:
-35.98%
1Y Performance:
-85.58%
1-Day Range:
$1.05
$1.22
1-Week Range:
$1.00
$1.22
52-Week Range:
$0.7233
$8.0985
Brainstorm Cell Therapeutics Inc Stock (BCLI) Company Profile
Name
Brainstorm Cell Therapeutics Inc
Sector
Industry
Phone
201-488-0460
Address
1325 AVENUE OF AMERICAS, NEW YORK, NY
Compare BCLI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCLI
Brainstorm Cell Therapeutics Inc
|
1.12 | 8.81M | 0 | -16.63M | -21.84M | -0.43 |
|
ONC
Beone Medicines Ltd Adr
|
245.68 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.96 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.34 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
494.05 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Brainstorm Cell Therapeutics Inc Stock (BCLI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-21 | Upgrade | Maxim Group | Hold → Buy |
| Nov-17-20 | Downgrade | Maxim Group | Buy → Hold |
| Dec-19-16 | Reiterated | Maxim Group | Buy |
| Dec-22-15 | Reiterated | Maxim Group | Buy |
Brainstorm Cell Therapeutics Inc Stock (BCLI) Latest News
What is Zacks Small Cap’s Estimate for BCLI FY2025 Earnings? - Defense World
Q2 Earnings Estimate for BCLI Issued By Zacks Small Cap - Defense World
BrainStorm Cell Therapeutics and Minaris partner on manufacturing NurOwn for trial - Yahoo Finance
BCLI: Receives Regulatory Clearance to Initiate Phase 3b ALS Trial… - Yahoo Finance
BrainStorm partners with Minaris for ALS therapy trial By Investing.com - Investing.com India
BrainStorm partners with Minaris for ALS therapy trial - Investing.com Australia
BrainStorm Cell Therapeutics (BCLI) Partners with Minaris for Nu - GuruFocus
BrainStorm Cell Therapeutics (BCLI) Partners with Minaris for NurOwn Manufacturing | BCLI Stock News - GuruFocus
BrainStorm Accelerates NurOwn ALS Treatment Development Through Major Manufacturing Deal with Minaris - Stock Titan
INVESTOR ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 2, 2024 in Brainstorm Cell Lawsuit – BCLI - ACCESS Newswire
FDA clears Phase 3b trial of NurOwn for ALS - ALS News Today
Gene And Cell Therapies Targeting Cns Disorders Market in 2025 - openPR.com
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Earns Hold Rating from Analysts at StockNews.com - Defense World
Brainstorm Cell Therapeutics outlines imminent Phase 3b ALS trial launch following FDA clearance and expanded manufacturing plans - MSN
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q1 2025 Earnings Call Transcript - Insider Monkey
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
What Did We Note About Insider Trading At Brainstorm Cell Therapeutics, Inc (NASDAQ: BCLI)? - Stocksregister
FDA grants clearance to BrainStorm’s Phase IIIb trial of ALS treatment - Yahoo Finance
Brainstorm Cell Therapeutics Reports Q1 2025 Financials - TipRanks
BrainStorm advances ALS treatment with FDA trial nod By Investing.com - Investing.com South Africa
BrainStorm advances ALS treatment with FDA trial nod - Investing.com Australia
Sector Update: Health Care Stocks Advance Monday Afternoon - marketscreener.com
Top Midday Gainers - marketscreener.com
BrainStorm (BCLI) Options Delisting Announced | BCLI Stock News - GuruFocus
Brainstorm Cell Therapeutics (BCLI) Advances Phase 3b ALS Trial - GuruFocus
Earnings call transcript: BrainStorm Cell Therapeutics Q1 2025 sees stock surge after trial updates - Investing.com Nigeria
Micro Cap Bid Up Aggressively On FDA Clearance Announcement - The Globe and Mail
Transcript : Brainstorm Cell Therapeutics Inc., Q1 2025 Earnings Call, May 19, 2025 - marketscreener.com
BrainStorm (BCLI) Receives FDA Green Light for NurOwn Phase 3b A - GuruFocus
BrainStorm Cleared by FDA to Begin Phase 3b Trial of NurOwn for ALS - marketscreener.com
Breaking ALS Treatment News: FDA Gives Green Light to BrainStorm's Crucial Phase 3b NurOwn Trial - Stock Titan
SEC Form DEFA14A filed by Brainstorm Cell Therapeutics Inc. - Quantisnow
BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update - StreetInsider
BrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025 - PR Newswire
BrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19 - The Malaysian Reserve
SEC Form 10-Q filed by Brainstorm Cell Therapeutics Inc. - Quantisnow
Brainstorm Cell Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
BrainStorm's NurOwn ALS Treatment Takes Major Step Forward: FDA Amendment Filed, Trial Sites Ready - Stock Titan
BrainStorm Reschedules First Quarter 2025 Financial Results Rele - GuruFocus
BrainStorm Cell Therapeutics Moves Q1 2025 Earnings Release to Today, Full Management Team to Host May 19 Call - Stock Titan
StockNews.com Begins Coverage on Brainstorm Cell Therapeutics (NASDAQ:BCLI) - Defense World
Brainstorm Cell Therapeutics (BCLI) to Release Earnings on Thursday - Defense World
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q4 2024 Earnings Call Transcript - MSN
Stem Cell Therapy Market 2025: Technical Signs Point Higher Growth Levels - newstrail.com
SHAREHOLDER ALERT: Potential Recovery for Brainstorm Cell Therapeutics Inc. (BCLI) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
BrainStorm to Present Biomarker Insights Supporting NurOwn's Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development Summit - Nasdaq
BrainStorm's ALS Treatment Breakthrough: New Biomarker Data Shows Promise as FDA-Approved Trial Approaches - Stock Titan
Geode Capital Management LLC Sells 630,315 Shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Defense World
5 Best Stem Cell Companies to Invest In (May 2025) - Securities.io
Press Release Distribution & PR Platform - ACCESS Newswire
INVESTOR ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 2, 2024 in Brainstorm Cell LawsuitBCLI - ACCESS Newswire
Brainstorm Cell Therapeutics Inc Stock (BCLI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Brainstorm Cell Therapeutics Inc Stock (BCLI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lebovits Chaim | President & CEO |
Sep 30 '24 |
Buy |
0.23 |
22,000 |
5,016 |
1,186,865 |
| Dagher Ibrahim B. | Chief Medical Officer |
Jul 19 '24 |
Sale |
0.35 |
63,000 |
22,069 |
0 |
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):